Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Open-label Phase 2 Dose-ranging Trial of Ponatinib in Resistant Chronic Phase CML
2024-514516-27-00Phase 2Completed
- Sponsor
- Takeda
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 2, randomised, open-label trial of ponatinib in chronic myelogenous leukemia (CML) (3 arms), sponsored by Takeda. Primary endpoint: ≤ 1% BCR-ABL1IS at 12 months. Started Oct 2024; status: completed.
02
Drugs
ponatinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2024-514516-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514516-27-00.